KR102635938B1 - 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 - Google Patents

양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 Download PDF

Info

Publication number
KR102635938B1
KR102635938B1 KR1020197018408A KR20197018408A KR102635938B1 KR 102635938 B1 KR102635938 B1 KR 102635938B1 KR 1020197018408 A KR1020197018408 A KR 1020197018408A KR 20197018408 A KR20197018408 A KR 20197018408A KR 102635938 B1 KR102635938 B1 KR 102635938B1
Authority
KR
South Korea
Prior art keywords
bipolar disorder
formula
bipolar
disorder
mania
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197018408A
Other languages
English (en)
Korean (ko)
Other versions
KR20190087572A (ko
Inventor
신유진
한세명
Original Assignee
에스케이바이오팜 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에스케이바이오팜 주식회사 filed Critical 에스케이바이오팜 주식회사
Publication of KR20190087572A publication Critical patent/KR20190087572A/ko
Application granted granted Critical
Publication of KR102635938B1 publication Critical patent/KR102635938B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020197018408A 2016-12-14 2017-12-14 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 Active KR102635938B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020160170224 2016-12-14
KR20160170224 2016-12-14
PCT/KR2017/014740 WO2018111008A1 (ko) 2016-12-14 2017-12-14 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도

Publications (2)

Publication Number Publication Date
KR20190087572A KR20190087572A (ko) 2019-07-24
KR102635938B1 true KR102635938B1 (ko) 2024-02-13

Family

ID=62559442

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197018408A Active KR102635938B1 (ko) 2016-12-14 2017-12-14 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도

Country Status (13)

Country Link
US (1) US11571410B2 (enExample)
EP (1) EP3556366B1 (enExample)
JP (1) JP7208139B2 (enExample)
KR (1) KR102635938B1 (enExample)
CN (1) CN110290788A (enExample)
AU (1) AU2017374458B2 (enExample)
BR (1) BR112019011930A2 (enExample)
CL (1) CL2019001618A1 (enExample)
IL (1) IL267195B2 (enExample)
MX (1) MX2019006940A (enExample)
MY (1) MY199104A (enExample)
WO (1) WO2018111008A1 (enExample)
ZA (1) ZA201903747B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3854391B1 (en) * 2018-09-21 2024-03-13 SK Biopharmaceuticals Co., Ltd. Carbamate compound and use of formulation comprising same in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder
WO2020060252A1 (ko) * 2018-09-21 2020-03-26 에스케이바이오팜 주식회사 중첩발작의 예방, 경감 또는 치료에 대한 카바메이트 화합물의 용도
AU2020389425A1 (en) * 2019-11-22 2022-06-02 Sk Biopharmaceuticals Co., Ltd. Oral pharmaceutical composition comprising carbamate compound and preparation method therefor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100843703B1 (ko) 2000-07-21 2008-07-04 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 양극성 장애에서의 조증을 치료하기 위한 벨프로익산 및 2-벨프로에닉산 아미드 유도체의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU6100A (sh) * 1997-08-14 2002-10-18 F.Hoffmann-La Roche Ag. Heterociklični viniletri protiv neuroloških poremećaja
ATE324108T1 (de) * 2001-02-27 2006-05-15 Ortho Mcneil Pharm Inc Carbamatverbindungen zur verwendung bei der prävention oder behandlung der bipolaren erkrankung
US7122576B2 (en) * 2001-02-27 2006-10-17 Plata-Salaman Carlos R Carbamate compounds for use in preventing or treating bipolar disorder
EA200701065A1 (ru) 2004-11-16 2007-12-28 Элан Фарма Интернэшнл Лтд. Инъецируемые составы, содержащие нанодисперсный оланзапин
US7598279B2 (en) 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
US20080103199A1 (en) * 2006-10-31 2008-05-01 Haas Magali Treatment of pervasive developmental disorders
BRPI0924997B1 (pt) 2009-06-22 2024-01-16 Sk Biopharmaceuticals Co., Ltd Método para preparar um composto de éster do ácido 1-aril-2- tetrazoil etil carbâmico
US8404461B2 (en) 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
US9610274B2 (en) * 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US9981950B2 (en) 2014-08-15 2018-05-29 Janssen Pharmaceuticals, Inc. Triazoles as NR2B receptor inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100843703B1 (ko) 2000-07-21 2008-07-04 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 양극성 장애에서의 조증을 치료하기 위한 벨프로익산 및 2-벨프로에닉산 아미드 유도체의 용도

Also Published As

Publication number Publication date
US20190314337A1 (en) 2019-10-17
IL267195B1 (en) 2024-01-01
AU2017374458B2 (en) 2023-03-02
CA3046297A1 (en) 2018-06-21
CL2019001618A1 (es) 2019-08-23
CN110290788A (zh) 2019-09-27
EP3556366B1 (en) 2025-10-22
ZA201903747B (en) 2021-01-27
KR20190087572A (ko) 2019-07-24
IL267195A (enExample) 2019-07-31
EP3556366A4 (en) 2020-06-17
IL267195B2 (en) 2024-05-01
EP3556366A1 (en) 2019-10-23
RU2019121913A (ru) 2021-01-15
RU2019121913A3 (enExample) 2021-04-21
BR112019011930A2 (pt) 2019-10-29
US11571410B2 (en) 2023-02-07
MY199104A (en) 2023-10-13
MX2019006940A (es) 2019-09-06
AU2017374458A1 (en) 2019-07-04
JP2020502106A (ja) 2020-01-23
WO2018111008A1 (ko) 2018-06-21
JP7208139B2 (ja) 2023-01-18

Similar Documents

Publication Publication Date Title
US20220184075A1 (en) Pharmaceutical composition containing hdac6 inhibitor as active ingredient for prevention or treatment of itching
JP7071287B2 (ja) 繊維筋痛又は繊維筋痛の関連する機能的症候群を予防又は治療するためのカルバメート化合物の使用
KR102635938B1 (ko) 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
KR102421006B1 (ko) 두통의 예방학적 치료를 위한 카바메이트 화합물의 용도
US20200223838A1 (en) Methods of use of phenoxypropylamine compounds to treat depression
JP6960415B2 (ja) 三叉神経痛を予防又は治療する目的のためのカルバメート化合物の使用
JP7417595B2 (ja) てんかん重積状態の予防、軽減又は治療のためのカルバメート化合物の使用
RU2774970C2 (ru) Применение карбаматных соединений для профилактики, облегчения или лечения биполярного расстройства
EP3854391B1 (en) Carbamate compound and use of formulation comprising same in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder
KR102635931B1 (ko) 가려움증의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
KR20210062029A (ko) 카바메이트 화합물의 당뇨병성 말초 신경병증 또는 화학요법 유발 말초 신경병증의 예방, 완화 또는 치료를 위한 용도
RU2796295C2 (ru) Карбаматное соединение и применение включающей его композиции для профилактики, облегчения или лечения острого стрессового расстройства или посттравматического стрессового расстройства
HK40015213A (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
BR112018073556B1 (pt) Uso de um composto de carbamato

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601